Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Haematologic Malignancies
Latest Information Update: 18 Sep 2021
At a glance
- Drugs T cell replacement therapy (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 11 Aug 2020 Biomarkers information updated
- 24 Aug 2013 New trial record